Business context and reporting period
Onto Innovation designs, manufactures, and supports process-control equipment and software for semiconductor and advanced-packaging manufacturers. The filing is a Form 10-Q for the quarter ended July 2, 2022, with six-month results compared with the periods ended June 26, 2021. The request metadata says “2020 Q2,” but the filing itself clearly reports 2022 Q2.
Key financial results
Amounts are in millions of dollars except per-share data. Fiscal quarters are not necessarily identical in length.
| Metric | Q2 2022 | Q2 2021 | Six months 2022 | Six months 2021 |
|---|---|---|---|---|
| Revenue | $256.3 | $193.4 | $497.7 | $362.7 |
| Gross profit | $132.1 | $105.5 | $263.2 | $195.9 |
| Gross margin | 51.5% | 54.5% | 52.9% | 54.0% |
| Operating income | $57.5 | $35.9 | $116.2 | $63.4 |
| Net income | $51.6 | $35.1 | $104.9 | $59.2 |
| Diluted EPS | $1.03 | $0.71 | $2.10 | $1.19 |
Q2 revenue grew 32.5% year over year and 6.2% sequentially; six-month revenue increased 37.2% year over year. Systems and software drove most revenue and growth. Management attributed sequential growth mainly to specialty-device advanced packaging and flash-memory advanced-node sales, partly offset by lower DRAM and foundry advanced-node sales.
Q2 gross margin declined year over year and from 54% in Q1 2022 to 51.5% in Q2. The filing cites product mix, including lower-margin lithography systems, increased manufacturing costs, and higher freight and logistics costs. Operating expenses were $74.7 million in Q2, versus $69.5 million a year earlier; management cited hiring, compensation, travel, new-product work, and litigation expense among the drivers. The Q2 effective tax rate was 10%, compared with 3% a year earlier; the 2021 comparison included a one-time tax benefit.
Cash flow, liquidity, and debt
For the first six months of 2022, operating cash flow was $55.4 million, down from $76.4 million in 2021. Increased accounts receivable and inventory contributed to an $87.6 million cash use from operating asset and liability changes. Investing activities used $33.2 million, including $6.9 million of capital expenditures; financing activities used $6.1 million. Cash and cash equivalents at quarter-end were $180.2 million, and marketable securities were $364.8 million, totaling $545.0 million. Working capital was $909.0 million.
The filing reports no borrowings outstanding. A securities-secured credit line provided approximately $125.2 million of availability at an indicated 3.3% rate and had not been used. Management said existing cash, securities, and credit availability should cover anticipated needs for the next 12 months. No shares were repurchased under the $100 million authorization during the period.
Outlook, risks, and unusual items
- The filing provides no specific revenue or earnings guidance. Management said first-half demand met or exceeded expectations and expected supply shortages and inflationary cost pressures to continue through the remainder of 2022.
- Supply-chain constraints, component shortages, longer lead times, freight costs, and inflation could delay deliveries, pressure margins, or cause lost sales. Inventory increased to $280.6 million from $243.1 million at fiscal year-end, while receivables rose to $234.7 million from $177.2 million.
- Sales are concentrated among major semiconductor customers and Asian markets. For the first six months, SK Hynix represented 17% of revenue, Taiwan Semiconductor Manufacturing 15%, and Samsung Semiconductor 11%. China and South Korea were the largest reported regional markets.
- Management said COVID-19 had not materially adversely affected operations to date, but warned that pandemic developments, export controls and U.S.-China trade tensions, geopolitical events, semiconductor-industry cyclicality, and customer concentration could affect results.
- A U.S. tax-law change requires capitalization and five-year amortization of certain R&D expenditures beginning in 2022; the company said this negatively affects cash flow. The effect of any legislative change was uncertain.
- The company accrued $2.2 million for a possible Inspectrology acquisition earnout, with up to $5.0 million of additional payment possible based on 2022 results. It also paid $2.3 million of previously earned contingent consideration during the first half.
- In the OSI litigation, discovery was ongoing, with trial scheduled for December 2023. The company characterized the loss contingency as remote and did not expect a material financial impact. Certain customer IP indemnification obligations have no reasonably estimable maximum; no amount was accrued.
- Marketable securities had $3.6 million of gross unrealized losses at quarter-end, which the company considered temporary. Foreign-currency translation and investment valuation changes reduced first-half comprehensive income by $12.0 million.
Important facts for investors to verify
- Confirm the period: this filing covers Q2 2022, not Q2 2020.
- Track whether supply constraints, cost inflation, and product mix continue to pressure gross margin and delivery performance.
- Monitor inventory and receivables growth against revenue, and the resulting conversion of earnings into operating cash flow.
- Assess exposure to large customers, Asian markets, export restrictions, and the semiconductor cycle.
- Review subsequent developments in the OSI case, the Inspectrology earnout, and tax-law treatment of R&D costs.